Novartis in 1999. Following the historic merger of Sandoz and Ciba, the giant Swiss firm struggled to turn its vision of a life sciences company into a commercial success. As top managers left, its share price suffered. Now Vasella is pushing it back along a familar track, seeking new blockbuster drugs, while making visionary investments in biotech companies as a means, of capturing more new ...
Year of publication: |
2000
|
---|---|
Authors: | Fallon, Padraic |
Published in: |
Euromoney. - London : Euromoney Publ, ISSN 0014-2433, ZDB-ID 1902325. - 2000, p. 44-61
|
Saved in:
Saved in favorites
Similar items by person
-
Value creation of capital markets
Fallon, Padraic, (2006)
-
The great deregulation explosion
Adam, Nigel, (1984)
-
Fallon, Padraic, (1994)
- More ...